Cogent Biosciences Says Patient Enrollment Is Now Complete In Phase 3 Peak Trial Evaluating Bezuclastinib In Combination With Sunitinib; Top-line Results Expected By End Of 2025
Portfolio Pulse from Benzinga Newsdesk
Cogent Biosciences has completed patient enrollment for its Phase 3 PEAK trial evaluating Bezuclastinib with Sunitinib. The trial enrolled 413 patients, and an interim analysis recommended continuation. Top-line results are expected by the end of 2025.
September 03, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cogent Biosciences completed enrollment for its Phase 3 PEAK trial ahead of schedule, with 413 patients. An interim analysis recommended continuing the trial, with results expected by end of 2025.
The completion of patient enrollment ahead of schedule and a positive interim analysis are positive indicators for Cogent Biosciences. These developments suggest strong progress in their clinical trial, which could boost investor confidence and potentially lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100